CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2009-10-23): Glaxo H1N1 shot works on children after one dose


Glaxo H1N1 shot works on children after one dose

Last Updated: 2009-10-23 16:00:56 -0400 (Reuters Health)

* Vaccine currently approved as two doses in children

* Glaxo says 150,000 people have received vaccine so far

LONDON (Reuters) - Britain's GlaxoSmithKline has shown that its H1N1 vaccine works in children after just one dose, potentially helping to ease the supply pressure as drugmakers rush to produce enough of the swine flu shot.

The vaccine, Pandemrix, is currently approved for use in two doses to children, but Glaxo said on Friday that governments might be able to change this to just one once the trial was completed.

Glaxo, the world's second biggest drugmaker, also said that 150,000 people have received the vaccine so far across Europe since mass vaccinations started last week.

Early results from the study showed that the vaccine worked after just one shot in all of the 200 children, aged between 6 and 36 months, that it tested.

Earlier on Friday, Europe's drugs watchdog, the European Medicines Agency, said that giving two doses of swine flu vaccine was preferable as the data so far was not conclusive.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.